8.61
+4.36%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BGM Group
Its shares trade under the ticker BGM. It has been listed since 12 January 2021. In the fiscal year to 30 September 2025, it reported revenue of $37.9m and a net loss of $19.9m. At that date it held total assets of $433.8m and shareholders' equity of $390.9m.
Qilian International Holding Group Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Jiuquan, Gansu. The company went IPO on 2021-01-12. Qilian International Holding Group Ltd is a China-based company mainly engaged in the development, manufacture, marketing and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives (TCMD) product, heparin product, sausage casings and fertilizers. The firm operates through three segments: Oxytetracycline & Licorice Products and TCMD segment, Fertilizer segment and Heparin Products and Sausage Casing segment. Its main brand is Qilian Shan. The firm principally operates its businesses within the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 12 Jan 2021
- Employees
- 323
- Website
- ir.qlsyy.net ↗
- Head office
- NO. 152 HONGLIANG EAST 1ST STREET, CHENGDU, 0000
- Incorporated in
- E9
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Emerging growth company
Leadership
Pay as last reported
- Mr. Zhanchang XinChairman of the Board, Chief Executive Officer, since 2006$17,939
- Ms. Haiping ShiChief Financial Officer, Director, since 2015$14,583
- Mr. Ming JingIndependent Director
- Mr. Yixuan SunIndependent Director
- Ms. Qingling ZhangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Qilian International Holding Group Ltd employs 323 employees in Jiuquan, CN, focusing on pharmaceuticals.
- The company's main brand Qilian Shan specializes in licorice and TCMD products for domestic markets.
- Operating through three segments, the firm manages oxytetracycline, heparin, and fertilizer products effectively.
Weaknesses
- The company's domestic market focus limits international expansion opportunities.
- Limited employee count of 323 may hinder large-scale production capabilities.
- Reliance on traditional Chinese medicine derivatives could face market saturation risks.
Opportunities
- Expanding into international markets could leverage the growing demand for Chinese pharmaceuticals.
- Increasing global demand for heparin products presents a significant growth opportunity.
- The fertilizer segment can benefit from agricultural sector growth in CN.
Threats
- Domestic market saturation may reduce profitability for licorice products.
- Regulatory changes in CN's pharmaceutical industry could impact operations.
- Competition from domestic pharmaceutical firms may affect market share.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.